Catheter ablation of atrial fibrillation: Current status and near future

Area of Science:

• Cardiology
• Electrophysiology

Background:

• Atrial fibrillation (AF) is a common arrhythmia impacting quality of life (QOL), mortality, and morbidity.
• Catheter ablation is a primary curative treatment for AF, focusing on symptom relief and QOL improvement.
• While established for symptomatic AF, ablation is increasingly used for asymptomatic cases, with guidelines suggesting a Class IIb recommendation.

Purpose of the Study:

• To evaluate the impact of AF catheter ablation on patient prognosis.
• To explore the efficacy and safety of novel ablation technologies, such as pulsed-field ablation.

Main Methods:

• Review of recent large-scale randomized controlled trials (RCTs) on AF ablation outcomes.
• Analysis of non-RCT studies investigating ablation's effect on AF patient prognosis.
• Introduction of pulsed-field ablation as a non-thermal energy source for tissue ablation.

Main Results:

• Large RCTs have not provided clear evidence of improved long-term prognosis with AF ablation.
• Non-RCT studies suggest potential prognostic benefits of ablation, even in asymptomatic patients.
• Pulsed-field ablation utilizes irreversible electroporation, offering a potentially safer alternative due to its non-thermal mechanism and tissue specificity.

Conclusions:

• The prognostic benefits of AF ablation require further investigation, despite its established role in symptom management.
• Current guidelines support ablation for asymptomatic AF, though evidence for prognostic improvement is limited.
• Pulsed-field ablation presents a promising advancement in AF treatment, potentially enhancing safety profiles compared to traditional methods.